Our top pick for
Travere Therapeutics, Inc is a biotechnology business based in the US. Travere Therapeutics shares (RTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 221 staff and has a trailing 12-month revenue of around USD$194 million.
Since the stock market crash in March caused by coronavirus, Travere Therapeutics's share price has had significant positive movement.
Its last market close was USD$24.11, which is 28.33% up on its pre-crash value of USD$17.28 and 168.49% up on the lowest point reached during the March crash when the shares fell as low as USD$8.98.
If you had bought USD$1,000 worth of Travere Therapeutics shares at the start of February 2020, those shares would have been worth USD$690.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,543.52.
|Latest market close||USD$24.11|
|52-week range||USD$8.98 - USD$24.96|
|50-day moving average||USD$21.3801|
|200-day moving average||USD$19.0224|
|Wall St. target price||USD$31.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.417|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-13)||1.82%|
|1 month (2020-10-22)||14.37%|
|3 months (2020-08-21)||30.11%|
|6 months (2020-05-22)||44.72%|
|1 year (2019-11-22)||76.24%|
|2 years (2018-11-21)||-6.62%|
|3 years (2017-11-22)||12.56%|
|5 years (2015-11-20)||24.09%|
|Revenue TTM||USD$194 million|
|Gross profit TTM||USD$170.1 million|
|Return on assets TTM||-6.61%|
|Return on equity TTM||-28.53%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 4.8 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 1.6% up from 4.7 million last month.
There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.
Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 265521.38121547). Travere Therapeutics's SIR currently stands at 18.1. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 18100 shares are currently held short.
However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 104 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Travere Therapeutics.
Find out more about how you can short Travere Therapeutics stock.
We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.
Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.
Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $8.98 up to $24.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.721. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.